USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
IMMURX LLC
Address:
16 Cavendish Court
LEBANON, NH
Phone:
N/A
URL:
N/A
EIN:
183046987
DUNS:
781013615
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,344,672.00 5
SBIR Phase II $2,776,441.00 1

Award List:

Potent Vaccine Adjuvant Therapeutic

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$577,222.00
Agency:
HHS
Principal Investigator:
Hillary D. White
Abstract:
DESCRIPTION (provided by applicant): Protective immunity against chronic infectious diseases such as TB will almost certainly require the generation of potent cellular immunity. To that end, we have recently developed a proprietary form of immunization (co mbined TLR/CD40-agonist immunization) which… More

Creation of an Anti-CD40 Superagonistic Monoclonal Antibody

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$329,936.00
Agency:
HHS
Principal Investigator:
Abstract:
Description: The overall goal of this revised SBIR application is to produce and test monoclonal antibodies (mab) to human CD40 that possess super-agonistic activity, as part of an adjuvant platform. The term superagonist is defined by specific immuno logical activities that these mabs possess,… More

Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$537,514.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The early infiltration by leukocytes into the tumor microenvironment leads to neovascularization, enhanced tumor growth, metastasis and lethality of the host. Notably, leukocytes enable tumor establishment, as suggeste d early on by Virchow in 1826 and proven… More

VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Susan D. Jones – 603-321-6623
Abstract:
DESCRIPTION (provided by applicant): We have discovered, characterized and functionally defined a novel, immune inhibitory ligand. This ligand is hematopoietically-expressed, a distant member of the B7 Ig-superfamily, and its extracellular domain bears homology to the B7 family ligand PD-L1. This… More

Preclinical Development of a Novel and Powerful Immunotherapeutic

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$2,776,441.00
Agency:
HHS
Principal Investigator:
Susan D. Jones – 603-321-6623
Abstract:
DESCRIPTION (provided by applicant): ImmuRx is developing a novel and potent immunotherapeutic product to stimulate the immune system. This will significantly increase the efficacy of existing and new therapeutic vaccines for the treatment of cancers suchas melanoma, lymphoma and lung cancer and… More

Safe and effective anti CD154 antibodies for therapeutic intervention

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Susan D. Jones – 603-321-6623
Abstract:
DESCRIPTION (provided by applicant): In both animal proof of concept studies and preliminary clinical trials, there is ample data demonstrating the potential therapeutic benefits o CD154 blockade for treatment of autoimmune diseases and organ transplantation. However, development of ?CD154 as a… More